Clinical Trial Update: Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pegilodecakin with FOLFOX versus FOLFOX alone as second-line therapy in metastatic pancreatic cancer; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• FOLFOX
• Pegilodecakin (pegilodecakin)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Pancreatic Cancer | Phase 3 | Status: COMPLETED | Results posted: 2020-10-19